Eli Lilly partners with Chinese institution to advance the nation’s diabetes and CVD care
pharmafile | April 27, 2018 | News story | Medical Communications, Research and Development | China, Eli Lilly, cardiovascular disorders, cvd, diabetes, pharma, type 2 diabetes
EIi Lilly has announced plans to partner up with China’s National Center for Cardiovascular Diseases (NCCD), the nation’s institution responsible for the development of programmes to combat the prominent health threat, in order to promote better scientific understanding and patient care for those affected by type 2 diabetes and cardiovascular disorders (CVD).
The collaboration will hinge upon four strategic initiatives to effectively assess China’s health economic consequences of diabetes, as well as examine patient samples to detect new biomarkers for progression of diabetes, diabetic kidney diseases (DKD) and CVD. To this end, the two parties will work to develop a CVD risk calculator to improve screening and disease management at a primary level of care.
The partnership will also see the creation and distribution of diabetes-related CVD medical education literature to healthcare professionals in the country.
“As the number of people living with diabetes continues to grow rapidly throughout China, it is imperative that we address the human and economic impact of the condition,” explauined NCCD Assistant Director Lixin Jiang. “Diabetes often leads to complications, including cardiovascular disease. By advancing our understanding of diabetes and cardiovascular disease, we have an opportunity to significantly improve care for people in China.”
Diabetes prevalence in China has increased by around 10% from 1% in 1980 to 2017.
The project will analyse data from the patient-centred Evaluative Assessment of Cardiac Events (PEACE) Million Persons Project, in total accessing the data of an estimated one million citizens with type 2 diabetes and increased CVD risk.
Lilly’s Robert Heine remarked: “Our hope is this collaboration will produce learning and tools that will benefit people living with type 2 diabetes in China and elsewhere around the world.”
Matt Fellows
Related Content
Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity
Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated …
CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
Roche shares data on novel solution for continuous glucose monitoring
Roche has shared the latest data on its novel solution for continuous glucose monitoring (CGM), …
